Novavax Contract UK: Everything You Need to Know
Novavax Contract UK is a topic that has been making headlines for the past few weeks, and for good reason. Novavax, a biotechnology company based in Maryland, USA, has secured a deal with the UK government to supply 60 million doses of its Covid-19 vaccine. In this article, we will take a closer look at Novavax Contract UK and everything you need to know about it.
What is Novavax?
Novavax is a biotechnology company that specializes in the discovery, development, and commercialization of vaccines. Novavax has a pipeline of vaccine candidates for a range of infectious diseases, including Covid-19. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland, USA.
What is Novavax Contract UK?
Novavax Contract UK is a deal between Novavax and the UK government to supply 60 million doses of Novavax`s Covid-19 vaccine. The deal includes the purchase of 60 million doses of the vaccine, as well as an agreement for Novavax to manufacture the vaccine in the UK.
The Novavax Covid-19 vaccine is a protein subunit vaccine that contains a piece of the Covid-19 virus called the spike protein. The vaccine is designed to trigger an immune response that can protect against Covid-19 infection.
Why is Novavax Contract UK significant?
Novavax Contract UK is significant for several reasons. Firstly, it represents a major investment in the production of Covid-19 vaccines in the UK. Novavax will manufacture its vaccine at a facility in Stockton-on-Tees, which will create jobs and help to build the UK`s capacity for vaccine production.
Secondly, the Novavax vaccine has shown promising results in clinical trials. In a Phase 3 trial conducted in the UK, the Novavax vaccine was found to be 89.3% effective in preventing Covid-19 infection. The vaccine is also effective against the UK variant of the virus, which is highly transmissible.
Thirdly, the Novavax vaccine is a different type of vaccine to those already approved for use in the UK. The Pfizer-BioNTech and Oxford-AstraZeneca vaccines are both based on mRNA and viral vector technology, whereas the Novavax vaccine is a protein subunit vaccine. This diversity in vaccine technology is important for ensuring that the world has a range of effective vaccines that can be used to fight Covid-19.
When will the Novavax vaccine be available in the UK?
The Novavax vaccine is currently undergoing regulatory approval by the Medicines and Healthcare products Regulatory Agency (MHRA). If the vaccine is approved, it is expected to become available in the UK in the second half of 2021.
In conclusion, Novavax Contract UK is an important development in the global fight against Covid-19. The deal represents a major investment in vaccine production in the UK, and the Novavax vaccine has shown promising results in clinical trials. If approved, the vaccine will provide the UK with another effective tool to combat Covid-19 and help to bring an end to the pandemic.
